Patient characteristics
| Characteristic . | N (%) . |
|---|---|
| Age, y | |
| Median | 31 |
| Range | 18-58 |
| 50+ | 11 (7) |
| Race | |
| White | 137 (84) |
| Black or African American | 11 (7) |
| Asian | 4 (2) |
| Not reported/unknown | 12 (7) |
| Sex | |
| Male | 88 (54) |
| Female | 76 (46) |
| Stage | |
| IA | 19 (12) |
| IB | 3 (2) |
| IIA | 92 (56) |
| IIB | 37 (23) |
| IIAE | 2 (1) |
| IIBE | 2 (1) |
| Not reported/unknown | 9 (5) |
| Total stage B | 42 (26) |
| Performance score | |
| ECOG/Zubrod = 0 | 121 (74) |
| ECOG/Zubrod = 1 | 35 (21) |
| Not reported/unknown | 8 (5) |
| ESR | |
| <50 | 108 (66) |
| 50+ | 41 (25) |
| Not reported/unknown | 15 (9) |
| GHSG* | |
| Favorable | 60 (40) |
| Unfavorable | 89 (60) |
| EORTC/LYSA/FIL* | |
| Favorable | 88 (59) |
| Unfavorable | 61 (41) |
| Characteristic . | N (%) . |
|---|---|
| Age, y | |
| Median | 31 |
| Range | 18-58 |
| 50+ | 11 (7) |
| Race | |
| White | 137 (84) |
| Black or African American | 11 (7) |
| Asian | 4 (2) |
| Not reported/unknown | 12 (7) |
| Sex | |
| Male | 88 (54) |
| Female | 76 (46) |
| Stage | |
| IA | 19 (12) |
| IB | 3 (2) |
| IIA | 92 (56) |
| IIB | 37 (23) |
| IIAE | 2 (1) |
| IIBE | 2 (1) |
| Not reported/unknown | 9 (5) |
| Total stage B | 42 (26) |
| Performance score | |
| ECOG/Zubrod = 0 | 121 (74) |
| ECOG/Zubrod = 1 | 35 (21) |
| Not reported/unknown | 8 (5) |
| ESR | |
| <50 | 108 (66) |
| 50+ | 41 (25) |
| Not reported/unknown | 15 (9) |
| GHSG* | |
| Favorable | 60 (40) |
| Unfavorable | 89 (60) |
| EORTC/LYSA/FIL* | |
| Favorable | 88 (59) |
| Unfavorable | 61 (41) |
ECOG, Eastern Cooperative Oncology Group; EORTC, European Organisation for Research and Treatment of Cancer; ESR, erythrocyte sedimentation rate; FIL, Fondazione Italiana Linfomi; GHSG, German Hodgkin Study Group; LYSA, Lymphoma Study Association.
Calculated only for those included in primary analysis (N = 149).